ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002 - First-in-class checkpoint inhibitor IOS-1002 (targeting LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1) being evaluated as mono and combination therapy in patients with advanced solid tumors Schlieren...

ImmunOs Therapeutics Receives Regulatory Approval for First-In-Human Trial of IOS-1002 - Lead compound IOS-1002 to be studied as mono and combination therapy in patients with advanced solid tumors- First patients to be enrolled in Q1, 2023 Schlieren (Zurich Area), Switzerland –...

Cofactor Genomics announces new collaboration with the National Cancer Institute (NCI) to demonstrate power of RNA-based immune profiling assay SAN FRANCISCO, March 20, 2018 (GLOBE NEWSWIRE) -- Cofactor Genomics, leading developer of advanced RNA analysis tools, announced today that they have entered into an agreement with the National...